305 reports of this reaction
1.3% of all CRIZOTINIB reports
#19 most reported adverse reaction
PLEURAL EFFUSION is the #19 most commonly reported adverse reaction for CRIZOTINIB, manufactured by Pfizer Laboratories Div Pfizer Inc. There are 305 FDA adverse event reports linking CRIZOTINIB to PLEURAL EFFUSION. This represents approximately 1.3% of all 22,895 adverse event reports for this drug.
Patients taking CRIZOTINIB who experience pleural effusion should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PLEURAL EFFUSION is a less commonly reported adverse event for CRIZOTINIB, but still significant enough to appear in the safety profile.
In addition to pleural effusion, the following adverse reactions have been reported for CRIZOTINIB:
The following drugs have also been linked to pleural effusion in FDA adverse event reports:
PLEURAL EFFUSION has been reported as an adverse event in 305 FDA reports for CRIZOTINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
PLEURAL EFFUSION accounts for approximately 1.3% of all adverse event reports for CRIZOTINIB, making it a notable side effect.
If you experience pleural effusion while taking CRIZOTINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.